Tempest Therapeutics Expects to Disclose Data From TPST-1495 Phase 1 Combination Arm in Patients With Advanced Endometrial Cancer in 2025 >TPST
Tempest Therapeutics Expects to Disclose Data From TPST-1495 Phase 1 Combination Arm in Patients With Advanced Endometrial Cancer in 2025 >TPST
Tempest Therapeutics预计将于2025年披露TPSt-1495第1期联合用药研究结果，涉及爱文思控股子宫内膜癌症患者。>TPST
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间